当前位置: X-MOL 学术JAMA Dermatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
HLA Screening for Dapsone Hypersensitivity in India—A Long Way Ahead—In Reply
JAMA Dermatology ( IF 10.9 ) Pub Date : 2019-12-01 , DOI: 10.1001/jamadermatol.2019.2609
Hong Liu 1 , Zhenzhen Wang 1 , Furen Zhang 1
Affiliation  

In Reply We thank Dr Bishnoi and colleagues for their interest in our study1 and for sharing us with the current epidemic status of leprosy and the focus of the disease control activities in India.

India has the highest prevalence of leprosy, with 126 164 new patients diagnosed in 2017 (0.67 cases per 100 000 population), accounting for nearly 60% of the total number of newly diagnosed patients in the world (data from National Leprosy Eradication Programme). We also agree that leprosy control activities should unmistakably focus on sustaining the elimination status. However, based on the dapsone hypersensitivity syndrome (DHS) incidence rate of 0.8% to 1.6% among patients with leprosy in India that was cited by Dr Vinay and colleagues, the annual incidence of patients with DHS may range from 1000 to 2000. A worldwide DHS mortality rate of 9.9% has been reported.2 Therefore, a screening policy prior to initiation of dapsone should be gradually implemented to prevent the occurrence of DHS and associated mortality in patients with leprosy in the future.



中文翻译:

HLA筛查印度的氨苯砜超敏反应-任重道远-答复

在答复中,我们感谢Bishnoi博士及其同事对我们的研究1的关注,并向我们分享了麻风病的当前流行状况以及印度疾病控制活动的重点。

印度是麻风病患病率最高的国家,2017年诊断出126 164例新患者(每10万人中有0.67例),占世界新诊断患者总数的近60%(国家麻风根除计划的数据)。我们还同意,麻风控制活动应明确地集中于维持消灭状态。但是,根据Vinay博士及其同事引用的印度麻风患者中氨苯砜超敏综合征(DHS)的发生率为0.8%至1.6%的数据,DHS患者的年发病率可能在1000到2000之间。据报道,DHS死亡率为9.9%。2个 因此,应逐步实施氨苯砜治疗前的筛查政策,以防止今后麻风病人发生DHS和相关死亡率。

更新日期:2019-12-11
down
wechat
bug